vimarsana.com

Page 42 - பிரேசிலியன் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Brazil s COVID-19 cases exceed 13 mln

Brazil s COVID-19 cases exceed 13 mln ANI | Updated: Apr 06, 2021 07:32 IST Brasilia [Brazil], April 6 (ANI/Xinhua): Brazil reported on Monday 28,645 new COVID-19 infections and 1,319 deaths in the past 24 hours, taking the nationwide tally to 13,013,601 and the national death toll to 332,752, the Health Ministry said on Monday. The South American country is one of the global epicenters of the COVID-19 pandemic, suffering the world s second-worst outbreak in terms of both deaths and infections, only after the United States. Last week, the Oswaldo Cruz Foundation, the most prominent science and technology health institution in Latin America attached to the Brazilian Ministry of Health, warned that hospitals in most parts of the country were under severe strain from a spike in COVID-19 infections, with ICU bed occupancy exceeding 90 per cent.

PlantForm signs agreement with Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab cancer drug

Share this article Share this article GUELPH, ON, and RIO DE JANEIRO, Brazil, April 6, 2021 /PRNewswire/ - PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) today announced a collaborative research and development agreement to develop a biosimilar pembrolizumab for the Brazilian market. The original antibody drug, pembrolizumab, is widely used in immunotherapy to treat a variety of cancers including melanoma, lung cancer, head and neck cancer, and stomach cancer. This agreement advances PlantForm s collaborations in Brazil to make affordable, effective cancer drugs available to millions of Brazilians, said Dr. Don Stewart, PlantForm s President and CEO. It also advances PlantForm s global strategy for biosimilar drug development and manufacturing to increase affordability and access to a wide range of life-saving medications.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.